NeoGenomics, Inc. (NEO)
| Market Cap | 2.11B |
| Revenue (ttm) | 644.12M |
| Net Income (ttm) | -77.73M |
| Shares Out | 128.36M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | 103.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,781,858 |
| Open | 16.19 |
| Previous Close | 16.40 |
| Day's Range | 16.19 - 16.60 |
| 52-Week Range | 12.77 - 21.22 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 20.30 (+23.71%) |
| Earnings Date | Feb 18, 2025 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detect... [Read more]
Financial Performance
In 2023, NeoGenomics's revenue was $591.64 million, an increase of 16.07% compared to the previous year's $509.73 million. Losses were -$87.97 million, -39.02% less than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NEO stock is "Strong Buy." The 12-month stock price forecast is $20.3, which is an increase of 23.71% from the latest price.
News
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH.
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, ...
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830).
Felicia Williams Joins NeoGenomics Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors.
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Execut...
NeoGenomics Reports Third Quarter 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2024.
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has received conditional approval from the NYSDOH for its Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung test.
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024.
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' AML Express is an NGS assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia.
NeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2
Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81.
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announces new RaDaR technology and resolution of RaDaR 1.0 litigation.
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present three studies at the European Society for Medical Oncology Congress in Barcelona, Spain, September 13-17 (booth #438).
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, Sept. 6, 2024 at 10:45 a.m. ET in New York City.
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
NeoGenomics Reports Second Quarter 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2024.
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024.
Fort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer Month
FORT MYERS, Fla.--(BUSINESS WIRE)--Fort Myers' Mayor, Kevin Anderson, will be proclaiming June as NeoGenomics' Commitment to Cancer Month.
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the...
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at ASCO 2024 in Chicago (booth #31093).
NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Comm...
NeoGenomics Reports First Quarter 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. announced its first-quarter results for the period ended March 31, 2024.
NeoGenomics Announces Senior Leadership Promotions
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2024 financial results on Tuesday, April 30, 2024.